UGT1A1 and neutropenia: It highlights individuals with specific UGT1A1 genetic variations—such as double heterozygotes for *6 and *28, or homozygotes for *6 or *28, are at risk of delayed SN-38 metabolism, which can lead to serious adverse drug reactions such as neutropenia.